QRG Capital Management Inc. Acquires 20,558 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

QRG Capital Management Inc. boosted its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 12.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 182,587 shares of the company’s stock after acquiring an additional 20,558 shares during the quarter. QRG Capital Management Inc. owned 0.08% of Hims & Hers Health worth $4,415,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HIMS. Creative Planning grew its stake in shares of Hims & Hers Health by 18.1% in the third quarter. Creative Planning now owns 25,925 shares of the company’s stock worth $478,000 after purchasing an additional 3,979 shares during the last quarter. International Assets Investment Management LLC acquired a new position in Hims & Hers Health during the 3rd quarter worth about $6,790,000. Robeco Institutional Asset Management B.V. bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at about $604,000. Olympiad Research LP bought a new position in shares of Hims & Hers Health during the third quarter worth about $262,000. Finally, Principal Financial Group Inc. lifted its stake in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after acquiring an additional 146,621 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Hims & Hers Health news, CEO Andrew Dudum sold 33,513 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.38, for a total transaction of $1,118,663.94. Following the sale, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at $1,118,296.76. This represents a 50.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Soleil Boughton sold 268,932 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the transaction, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 1,097,578 shares of company stock valued at $38,080,320. 17.71% of the stock is owned by insiders.

Hims & Hers Health Trading Up 9.3 %

Shares of Hims & Hers Health stock opened at $45.20 on Friday. The stock has a fifty day simple moving average of $36.57 and a 200 day simple moving average of $26.66. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The company has a market capitalization of $9.87 billion, a P/E ratio of 102.72 and a beta of 1.35.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Ratings Changes

HIMS has been the subject of a number of recent analyst reports. TD Cowen reissued a “buy” rating and set a $28.00 target price on shares of Hims & Hers Health in a research report on Wednesday, November 20th. Citigroup lifted their target price on shares of Hims & Hers Health from $25.00 to $27.00 and gave the stock a “sell” rating in a research note on Tuesday. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. BTIG Research started coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Truist Financial boosted their price objective on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research note on Wednesday. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $37.23.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.